Time-dependent endpoints as predictors of overall survival in multiple myeloma | BMC Cancer | Full Text
Efficacy Data | Xofigo® (Radium Ra 223 Dichloride)
Correlation between overall survival and other endpoints in clinical trials of second-line chemotherapy for patients with advanced gastric cancer | SpringerLink
Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer | NEJM
Las 10 razas de perros medianos más populares
Overall survival in the SIMPLIFY-1 and SIMPLIFY-2 phase 3 trials of momelotinib in patients with myelofibrosis | Leukemia
Overall survival (OS) analyses. Case numbers, median OS and P-values... | Download Scientific Diagram
The median OS of the patients. OS, overall survival. | Download Scientific Diagram
Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC | NEJM
Third-Line Nivolumab Monotherapy in Recurrent SCLC: CheckMate 032
Median Overall Survival (mOS) | ENHERTU® (fam-trastuzumab deruxtecan-nxki)
Kaplan-Meier plots for survivals. In Figure 2A, a median OS of 9.1... | Download Scientific Diagram
Correlation between overall survival and other endpoints in clinical trials of second-line chemotherapy for patients with advanced gastric cancer | SpringerLink
Assessing the efficacy‐effectiveness gap for cancer therapies: A comparison of overall survival and toxicity between clinical trial and population‐based, real‐world data for contemporary parenteral cancer therapeutics - Phillips - 2020 - Cancer -
Time-dependent endpoints as predictors of overall survival in multiple myeloma | BMC Cancer | Full Text
Overall survival (OS) of all patients. The median OS is 26 months (95 %... | Download Scientific Diagram
Median overall survival (mOS) and median progression-free survival... | Download Scientific Diagram
Correlation between overall survival and other endpoints in clinical trials of second-line chemotherapy for patients with advanced gastric cancer | SpringerLink
The median OS of the patients. OS, overall survival. | Download Scientific Diagram
Predictive biomarkers for survival benefit with ramucirumab in urothelial cancer in the RANGE trial | Nature Communications
Axicabtagene ciloleucel as first-line therapy in high-risk large B-cell lymphoma: the phase 2 ZUMA-12 trial | Nature Medicine
Overall survival. Median OS was 13 months (95%Cl 9–16). | Download Scientific Diagram
Pegylated liposomal doxorubicin in patients with metastatic triple-negative breast cancer: 8-year experience of a single center | Journal of the Egyptian National Cancer Institute | Full Text
KarMMa Survival Rates | ABECMA® (idecabtagene vicleucel)
Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer | NEJM
Median Overall Survival (mOS) | ENHERTU® (fam-trastuzumab deruxtecan-nxki)
The prognosis of non-small cell lung cancer patients according to endobronchial metastatic lesion | Scientific Reports
Efficacy Data in Metastatic Colorectal Carcinoma | STIVARGA® (regorafenib) Global HCP Website
